Article
Oncology
Ines Moreira, Marta Ferreira, Sofia Garcia, Pedro Novais, Joao Gama, Beatriz Ferro, Pedro Leite-Silva, Cristina Frutuoso, Monica Pires, Ana Barbosa, Carla Pinto, Manuel R. Teixeira, Deolinda Pereira, Carla Bartosch
Summary: This study aimed to explore the practical aspects and difficulties in implementing the molecular classification of endometrial carcinoma (EC) and demonstrate its potential impact on prognostic risk group classification. The study achieved implementation through centralization of molecular analysis, and optimizing workflows by conducting genetic studies in endometrial biopsies before surgery and prioritizing patients whose results would change risk group classification.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Damiano Arciuolo, Antonio Travaglino, Antonio Raffone, Diego Raimondo, Angela Santoro, Daniela Russo, Silvia Varricchio, Paolo Casadio, Frediano Inzani, Renato Seracchioli, Antonio Mollo, Massimo Mascolo, Gian Franco Zannoni
Summary: The TCGA-based molecular prognostic groups of endometrial carcinoma (EC) have improved diagnosis, risk stratification, and management. POLE-mutant and MMR-deficient groups are associated with high mutational load, morphological heterogeneity, and inflammatory infiltration. POLE-mutant ECs have good prognosis and may not require adjuvant treatment. MMR-deficient ECs have intermediate prognosis and may benefit from immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Christine S. Walsh, Kari E. Hacker, Angeles Alvarez Secord, Deborah F. DeLair, Carolyn McCourt, Renata Urban
Summary: The Cancer Genome Atlas publication identified four molecular subtypes of endometrial cancer with different prognoses. The Proactive Molecular Classifier for Endometrial Cancer facilitates the classification of endometrial cancers into similar subtypes more conveniently and inexpensively. In addition to these subtypes, other molecular biomarkers may impact clinical behavior and response to targeted therapies. The understanding of molecular classification is essential for clinicians treating endometrial cancer to guide appropriate testing and treatment decisions.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Cristina Mitric, Marcus Q. Bernardini
Summary: Endometrial carcinoma can be classified into four molecular groups, which can assist in clinical decision-making for adjuvant treatment. This classification has implications for clinical trials and exploring novel treatments.
Article
Oncology
Allison M. Puechl, Daniel Spinosa, Andrew Berchuck, Angeles Alvarez Secord, Kerry E. Drury, Gloria Broadwater, Janice Wong, Regina Whitaker, Nicolas Devos, David L. Corcoran, Kyle C. Strickland, Rebecca A. Previs
Summary: Molecular classification can help predict treatment response in patients with endometrial cancer and EIN treated with levonorgestrel intrauterine system (LNG-IUS), aiding in identifying patients at risk of progression.
Article
Oncology
Seungyeon Joe, Miseon Lee, Jun Kang, Joori Kim, Sook-Hee Hong, Sung Jong Lee, Keun Ho Lee, Ahwon Lee
Summary: The study utilized POLE ddPCR and L1CAM IHC as alternative methods for molecular classification in early-stage endometrial cancer, enhancing risk stratification and providing valuable information for treatment decisions and patient outcomes.
Article
Oncology
Mikko Loukovaara, Annukka Pasanen, Ralf Butzow
Summary: In this retrospective study, the aggressiveness of MMR deficient endometrial carcinomas was examined. MMR deficiency was associated with poor disease-specific survival and increased risk of cancer-related death. The findings highlight the need for improved triage to adjuvant therapy and new therapeutic approaches in MMR deficient endometrial carcinomas.
Article
Oncology
Junhwan Kim, Se Ik Kim, Nae Ry Kim, Hyojin Kim, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Cheol Lee, Maria Lee
Summary: This study investigated the prognostic significance of L1 cell-adhesion molecule (L1CAM), β-catenin, and programmed death-ligand 1 (PD-L1) in endometrial cancer (EC) patients, with a focus on the p53 wild-type subgroup. The results showed that L1CAM positivity was associated with poor prognosis in EC and increased the risk of recurrence in the p53 wild-type subgroup.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Oncology
Brenna E. Swift, Lilian T. Gien
Summary: The treatment of endometrial cancer has shifted from traditional clinical-pathologic factors to molecular characterization, with new treatment approaches drastically changing the options for advanced and recurrent cases. However, further research is needed to better understand biomarkers for prognosis and targeted treatments.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Dario de Biase, Thais Maloberti, Angelo Gianluca Corradini, Francesca Rosini, Marco Grillini, Martina Ruscelli, Sara Coluccelli, Annalisa Altimari, Elisa Gruppioni, Viviana Sanza, Daniela Turchetti, Andrea Galuppi, Martina Ferioli, Susanna Giunchi, Giulia Dondi, Marco Tesei, Gloria Ravegnini, Francesca Abbati, Daniela Rubino, Claudio Zamagni, Pierandrea De Iaco, Donatella Santini, Claudio Ceccarelli, Anna Myriam Perrone, Giovanni Tallini, Antonio De Leo
Summary: This study compares the new ESGO/ESTRO/ESP risk stratification system with the previous 2016 recommendations for endometrial carcinoma patients. The results show that the new system provides more accurate identification of low-risk and high-risk patients, potentially allowing a more specific selection of patients for post-operative adjuvant therapy.
FRONTIERS IN MEDICINE
(2023)
Article
Oncology
Jessie Y. Li, Henry S. Park, Gloria S. Huang, Melissa R. Young, Elena Ratner, Alessandro Santin, Shari Damast
Summary: The study investigated the impact of mismatch repair (MMR) status on the prognosis of EEC patients treated with vaginal brachytherapy (VBT). It was found that patients with deficient MMR (dMMR) had poorer recurrence-free survival (RFS) compared to proficient MMR (pMMR) patients, regardless of their high-intermediate-risk (HIR) or low-intermediate-risk (LIR) classification.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sylvie Streel, Alixe Salmon, Adriane Dheur, Vincent Bours, Natacha Leroi, Lionel Habran, Katty Delbecque, Frederic Goffin, Clemence Pleyers, Athanasios Kakkos, Elodie Gonne, Laurence Seidel, Frederic Kridelka, Christine Gennigens
Summary: Molecular algorithms play a crucial role in estimating the risk of recurrence and death in patients with endometrial cancer (EC) and guiding treatment decisions. Immunohistochemistry (IHC) and molecular techniques are used to detect microsatellite instabilities (MSI) and p53 mutations. This study aims to assess the diagnostic performance of IHC compared to the gold standard of molecular techniques.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Mayumi Kobayashi-Kato, Erisa Fujii, Yuka Asami, Yuka Ahiko, Kengo Hiranuma, Yasuhisa Terao, Koji Matsumoto, Mitsuya Ishikawa, Takashi Kohno, Tomoyasu Kato, Kouya Shiraishi, Hiroshi Yoshida
Summary: This study compared the goodness of fit and discriminatory ability of three classification systems for endometrial cancer, and found that FIGO2023m had the best discriminatory ability. Additionally, p53 abnormalities were associated with lower survival rates in stage IIIC.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Mayumi Kobayashi Kato, Hiroshi Yoshida, Yasuhito Tanase, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato
Summary: The study found that the expression status of ARID1A is a prognostic factor for early-stage G3EEC patients without adjuvant therapy, while the expression status of p53 and MMR does not significantly impact survival outcomes. Therefore, ARID1A may become a useful biomarker for stratification of adjuvant treatment for early-stage G3EEC patients.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Review
Oncology
Colm Mac Eochagain, Robert Power, Imelda Parker, Donal Brennan
Summary: Patients with high-grade endometrial carcinoma exhibiting POLEmut have very good clinical outcomes, often presenting conflicting molecular characteristics and poor histological appearance.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)